Quarterly report pursuant to Section 13 or 15(d)

Selected Balance Sheet Data (Tables)

v3.22.1
Selected Balance Sheet Data (Tables)
9 Months Ended
Mar. 31, 2022
Notes Tables  
Schedule of Inventory, Current [Table Text Block]

Inventories consist of (in thousands):

​

​

​

​

​

​

​

​

​

    

March 31, 

​

June 30, 

​

    

2022

    

2021

Raw materials

​

$

69,263

​

$

55,096

Finished goods(1)

​

 

64,742

​

 

67,108

Inventories, net

​

$

134,005

​

$

122,204

​

(1) Finished goods inventory of $5,722 and $5,456 included within other long-term assets in the respective March 31, 2022 and June 30, 2021, consolidated balance sheet. The inventory is included in long-term assets as it is forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.

Property, Plant and Equipment [Table Text Block]

Property and equipment consist of (in thousands):

​

​

​

​

​

​

​

​

​

    

March 31, 

​

June 30, 

​

    

2022

    

2021

Land

​

$

8,603

​

$

8,612

Buildings and improvements

​

 

225,378

​

 

190,661

Machinery and equipment

​

​

164,665

​

​

149,410

Construction in progress

​

 

26,508

​

 

49,073

Property and equipment, cost

​

 

425,154

​

 

397,756

Accumulated depreciation and amortization

​

 

(206,756)

​

 

(189,849)

Property and equipment, net

​

$

218,398

​

$

207,907

Schedule of Intangible Assets and Goodwill [Table Text Block]

Intangible assets consist of (in thousands):

​

​

​

​

​

​

​

​

​

​

March 31, 

​

June 30, 

​

​

2022

​

2021

​

​

​

​

​

​

​

Developed technology

​

$

543,977

​

$

552,160

Trade names

​

 

147,311

​

 

147,640

Customer relationships

​

 

228,943

​

 

232,493

Patents

​

 

3,249

​

 

2,926

Other intangibles

​

 

6,313

​

 

6,316

Definite-lived intangible assets

​

 

929,793

​

 

941,535

Accumulated amortization

​

 

(401,151)

​

 

(348,267)

Definite-lived intangibles assets, net

​

 

528,642

​

 

593,268

In process research and development

​

 

22,700

​

 

22,700

Total intangible assets, net

​

$

551,342

​

$

615,968

Schedule of Finite-Lived Intangible Assets [Table Text Block]

Changes to the carrying amount of net intangible assets for the period ended March 31, 2022 consist of (in thousands):

​

​

​

​

​

​

​

​

​

Beginning balance

​

$

615,968

Acquisitions

​

 

—

Other additions

​

 

283

Amortization expense

​

 

(55,731)

Currency translation

​

 

(615)

Eminence impairment (1)

​

​

(8,563)

Ending balance

​

$

551,342

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

The estimated future amortization expense for intangible assets as of March 31, 2022 is as follows (in thousands):

​

​

​

​

​

2022 remainder

    

$

18,478

2023

​

 

71,725

2024

​

 

68,857

2025

​

 

65,621

2026

​

 

61,876

Thereafter

​

 

242,085

Total

​

$

528,642

​

(1) As disclosed in Note 1, the Company recorded an impairment charge of $8.6 million related to Eminence in Q2 of FY'22.

Schedule of Goodwill [Table Text Block]

Changes to the carrying amount of goodwill for the period ended March 31, 2022 consist of (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

    

​

    

Diagnostics and

    

​

​

​

Protein Sciences

​

 Genomics

​

Total

Beginning balance

​

$

392,717

​

$

450,350

​

$

843,067

Acquisitions(1)

​

 

—

​

 

(4,407)

​

 

(4,407)

Eminence impairment

​

​

(8,275)

​

​

—

​

​

(8,275)

Currency translation

​

 

(2,588)

​

 

(179)

​

 

(2,767)

Ending balance

​

$

381,854

​

$

445,764

​

$

827,618